Posted by hyperfocus on November 23, 2010, at 10:27:41
In reply to Re: Valdoxan availability, posted by Bob on November 19, 2010, at 19:40:10
"In March 2006, Servier announced it had sold the rights to market agomelatine in the United States to Novartis.[7] It is currently undergoing phase III clinical trials in the US. Novartis lists the drug as scheduled for submission to the FDA no earlier than 2012.[8] It is currently sold in Australia under the Valdoxan trade name."
poster:hyperfocus
thread:970772
URL: http://www.dr-bob.org/babble/20101117/msgs/971076.html